Table 4.
KEGG pathways of differentially expressed miRNAs in early glycaemic impairment
| p | n. of genes | n. of miRNAs | |
|---|---|---|---|
| A) KEGG pathway | |||
| Huntington’s disease | 0.000000019 | 3 | 1 |
| Hippo signalling pathway | 0.0000013 | 18 | 2 |
| Lysine degradation | 0.000046 | 8 | 1 |
| Protein processing in endoplasmic reticulum | 0.000239 | 25 | 1 |
| Proteoglycans in cancer | 0.002373 | 22 | 1 |
| Viral carcinogenesis | 0.004420 | 26 | 1 |
| Glycosaminoglycan biosynthesis - chondroitin sulfate/dermatan sulfate | 0.007630 | 2 | 1 |
| Colorectal cancer | 0.013249 | 3 | 1 |
| Central carbon metabolism in cancer | 0.023230 | 9 | 1 |
| Endocytosis | 0.026468 | 22 | 1 |
| Transcriptional misregulation in cancer | 0.027697 | 4 | 1 |
| Thyroid hormone signalling pathway | 0.038555 | 13 | 1 |
| FoxO signalling pathway | 0.041500 | 17 | 1 |
| Adherens junction | 0.041500 | 10 | 1 |
| B) KEGG pathway | |||
| Hippo signalling pathway | 0.00000139 | 18 | 2 |
A) Pathways enrichment analysis of single deregulated miRNAs. B) Pathways union of miRNAs is also reported. Pathways were classified according to KEGG functional annotations to identify top pathways that were actively regulated by miRNAs. Merged p-value is extracted by combining calculated significance levels using Fisher’s exact test (hypergeometric distribution) with a p-value threshold=0.05 and MicroT threshold=0.8